<DOC>
	<DOCNO>NCT00294372</DOCNO>
	<brief_summary>The general aim evaluate antiviral activity safety increase dos oral administer RTV-boosted BILR 355 BS ( 75 mg 150 mg twice daily ) HIV-1-infected , NNRTI-experienced patient , follow 28 day combination therapy Tipranavir Lopinavir base HAART-regimen</brief_summary>
	<brief_title>Phase II Study Antiviral Activity Safety BILR 355 BS HIV-1 Infected , NNRTI-treated Patients</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>1 . Signed informed consent accordance GCP local regulatory requirement prior trial participation . 2 . HIV1 infect male female &gt; = 18 year age . 3 . History NNRTI base HAART &gt; = 8 week least one , 3 NNRTIassociated resistance mutation current genotype 4 . TPV/r LPV/r susceptible 5 . CD4+ T lymphocyte count &gt; = 100 cells/ ? l . 7 . HIV1 viral load &gt; = 2000 copies/mL screen . 8 . Karnofsky score &gt; = 70 9 . Based antiviral resistance profile patient virus , investigator must able construct background HAART treatment regimen ( OBR ) patient receive 3 effective ARV drug , addition study medication . 10 . Acceptable screen laboratory value ( Visit 1 ) indicate adequate baseline organ function . Laboratory value consider acceptable follow apply : Absolute neutrophil count ( ANC ) &gt; 750/mm3 Hemoglobin &gt; = 10 g/dL Platelet count &gt; 99,000/mm3 AST , ALT , alkaline phosphatase &lt; 2.5xULN &gt; = DAIDS Grade 1 ) Total bilirubin &lt; 2.5xULN Serum amylase &lt; 1.5xULN 11 . Acceptable medical history , assess investigator , chest xray result ECG within 1 year study participation . 12 . Willingness abstain ingest substance may alter plasma study drug level interaction cytochrome P450 system 13 . A prior AIDS defining event , exclude mycobacterial invasive fungal infection , acceptable long resolve subject stable treatment ( e.g . opportunistic infection ) least 12 week screen ( Visit 1 ) . Note prior oral thrush , candida esophagitis cutaneous candida acceptable . 1 . The following resistance mutation demonstrate time prior start trial therapy : V106A and/or Y188L 2 . Female patient childbearing potential : positive serum pregnancy test screening study , breast feeding , plan become pregnant , willing use barrier method contraception . 3 . Active Hepatitis B C disease define HBsAg positive HCV RNA positive AST/ALT &gt; DAIDS Grade 1 4 . Acute/previous mycobacterial invasive fungal infection require therapy prophylaxis drug interfere significantly affect cytochrome P450 system 5 . Use investigational medication within 30 day study entry trial . 6 . Use concomitant drug may significantly reduce plasma level study medication . 7 . Use immunomodulatory drug within 30 day study entry trial ( e.g . interferon , cyclosporin , hydroxyurea , interleukin 2 ) . 8 . Patients currently treat systemic antcancer chemotherapy 9 . Inability adhere requirement protocol , include active substance abuse , define investigator . 10 . In opinion investigator , likely survival le 12 month underlying disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>